Experience of conservative treatment giant cell bone tumor

Giant-cell bone tumor (GCT) make up 15–20% all cases non-malignant bone tumor. treatment opportunities based on new understanding mechanism of osteoclastogenesis. Denosumab – fully humanized monoclonal antibody (IgG2) to RANK ligand.
Blocking of RANK ligand prevent bone resorption and increasing bone mass 18 patients conclude in study. From 16 to 65 y.o.
13 female and 5 male. Histological verification in all case. 120mg Denosumab per cutaneous injection in 1,8,15,28 days of first month and after that 1 injection per 28days. treatment duration – 18 month.
In all cases we have good and quick response – reduce pain, function recovery. x-ray picture after 2 month therapy show osteosclerosis of bone lesion and cortical layer recovery.
Conclusion Denosumab is a good treatment fore GCT. In case of unresected lesion and difficult localization may be is the single. more patients and time is need to further research